EUVIMEDEUVIMED entdecken
Crossref

An empirical single‐breakthrough curve workflow for rapid early‐phase development of continuous capture chromatography for monoclonal antibodies and mAb ‐derived proteins

Jay Gandhi iD, James Hilton iD, Kyo Izumida, Itaru Takeshita, Braden Chiulli iD, Thomas Higgins iD, Sami El Hamwi iD, Janine De Leon iD, Parinita Bhongale iD, Evan Graessle, Olga Paley, Mike Dolan und 4 weitere

Biotechnology Progress · 06.08.2026

DOI: 10.1002/btpr.88544 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Progress, online erschienen am 06.08.2026. Verfasst von Jay Gandhi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Biotherapeutics Process Development, Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA. Die Arbeit nennt 70 Literaturangaben. Gefördert von: Takeda Pharmaceuticals U.S.A..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Continuous chromatography for Protein A capture of monoclonal antibodies (mAbs) and related biotherapeutics is gaining popularity for higher throughput and reduced costs but introduces challenges for development and modeling. We present a streamlined, single‐breakthrough‐curve approach that predicts maximum and operating binding capacities (MBC and OBC, respectively) for continuous Protein A chromatography of monoclonal antibodies and derivatives. Our empirically‐calibrated model—intended for early‐stage, material‐limited process development—enables accurate OBC prediction (root mean squared error [RMSE]≤ 5% for four distinct proteins) using less than 1 g of protein. This approach reduces the experimental timeline by ~2 weeks and is best suited for rapid screening and initial process optimization, not full design‐space determination. Results confirm the model's accuracy across molecules, with clear practical advantages for accelerating preclinical pipeline advancement.

Schlagwörter

Stichwörter der Autor:innen

continuous bioprocessingmodelingmulti‐column chromatographysimulated moving bed (SMB)

Autor:innen und Institutionen

  • Biotherapeutics Process Development, Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA.

ORCID-Profile: Jay Gandhi, James Hilton, Braden Chiulli, Thomas Higgins, Sami El Hamwi, Janine De Leon, Parinita Bhongale, Sheldon Oppenheim, George Parks, Christina Alves

Förderung

  • Takeda Pharmaceuticals U.S.A.

Zitieren

APA

Gandhi, J., Hilton, J., Izumida, K., Takeshita, I., Chiulli, B., Higgins, T., El Hamwi, S., De Leon, J., Bhongale, P., Graessle, E., Paley, O., Dolan, M., Oppenheim, S., Parks, G., Dobrowsky, T., & Alves, C. (2026). An empirical single‐breakthrough curve workflow for rapid early‐phase development of continuous capture chromatography for monoclonal antibodies and mAb ‐derived proteins. Biotechnology Progress. https://doi.org/10.1002/btpr.88544

Vancouver

Gandhi J, Hilton J, Izumida K, Takeshita I, Chiulli B, Higgins T, et al. An empirical single‐breakthrough curve workflow for rapid early‐phase development of continuous capture chromatography for monoclonal antibodies and mAb ‐derived proteins. Biotechnology Progress. 2026. doi:10.1002/btpr.88544

BibTeX
@article{Gandhi2026,
  author = {Gandhi, Jay and Hilton, James and Izumida, Kyo and Takeshita, Itaru and Chiulli, Braden and Higgins, Thomas and El Hamwi, Sami and De Leon, Janine and Bhongale, Parinita and Graessle, Evan and Paley, Olga and Dolan, Mike and Oppenheim, Sheldon and Parks, George and Dobrowsky, Terrence and Alves, Christina},
  title = {An empirical single‐breakthrough curve workflow for rapid early‐phase development of continuous capture chromatography for monoclonal antibodies and mAb ‐derived proteins},
  journal = {Biotechnology Progress},
  year = {2026},
  doi = {10.1002/btpr.88544}
}
Kostenlos starten →